Liver Cancer Prevention and Screening
Liver cancers can be prevented by treating the causes before the liver develops scarring of the liver or what is known as cirrhosis. Hepatitis B and C are the known commonly known causes of cirrhosis in the world, until recently. Another condition known as fatty liver disease—also known as metabolic associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD)—has steadily been contributing to a greater number of liver cancer cases. Join this session to learn about what lifestyle choices and risk factors play into the causes of liver cancer and how it can be prevented.
Session participants will understand:
- Liver cancer screening, prevention, diagnosis and treatment
- Incidence, mortality and prevalence rates of breast cancer in Arizona
- Risks for developing liver cancer and how to lower them
- The role of genetic testing and family history in liver cancer diagnosis
- Treatment options for liver cancer
Mital Patel, MD, with Dignity Health Cancer Institute at St. Joseph’s Hospital and Medical Center.
Dr. Mital Patel is a Gastrointestinal Medical Oncologist at the Dignity Health – Cancer Institute at St. Joseph’s Hospital and Medical Center. Dr. Patel’s expertise includes management of all types of colorectal, gastro-esophageal and hepatobiliary cancers.
Dr. Patel received his medical degree from Seth G.S. Medical College/University of Mumbai in India. He completed his residency in Internal Medicine at Columbia University affiliated St. Luke’s Roosevelt Hospital Center in New York. Subsequently, he continued his academic career as a Staff Physician in the Department of Hospital Medicine at Cleveland Clinic. He completed a fellowship in Hematology and Oncology at Case Western Reserve University/ Seidman Cancer Center in Cleveland, Ohio where he focused on the management of gastrointestinal cancers. He is a member of the American Society of Clinical Oncology.
He specializes in the care of patients with colon and rectal cancers, stomach and esophageal malignancies, hepatobiliary and pancreatic malignancies and neuroendocrine tumors. He has a keen interest in developing clinical trials and improving patient access to them. He believes that compassionate cancer care is best delivered by a multidisciplinary team who can communicate and tailor treatment plans to the individual needs of the patient and their families.
For more information, contact Irene Cassidy at: